The 3PC Trial (Intraductal Papillary Mucinous Neoplasm) - Clinical Trial

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be randomized to Group 1 or Group 2
-- Group 1 will get the study drug (Sulindac)
-- Group 2 will get a placebo (harmless sugar pill)

Both groups will have:
- CT scans (body scan)
- Endoscopy's (a way to look at your digestive tract)
- Collection of cyst fluid from the pancreas

What is the Condition Being Studied?

Intraductal Papillary Mucinous Neoplasms (IPMN)

Who Can Participate in the Study?

- Men and women 21-85 years old
- Diagnosed with high-risk intraductal papillary mucinous neopolasm (IPMN)

Age Group
Adults

What is Involved?

We are doing this study to learn more about how the study drug, Sulindac, effects people with high risk intraductal papillary mucinous neoplasms (IPMN). The study drug (Sulindac) is a non-steroidal, anti-inflammatory medicine commonly called an NSAID.

Study Details

Full Title
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
Principal Investigator
Gastrointestinal Surgeon
Protocol Number
IRB: PRO00103684
NCT: NCT04207944
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698